Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivantinib - Merck & Co

Next Previous
X
Search
Drug Profile

Tivantinib - Merck & Co

Alternative Names: ARQ-197

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArQule
  • Developer Daiichi Sankyo Company; Istituto Clinico Humanitas; Istituto Oncologico Veneto; Kyowa Hakko Kirin; Kyowa Kirin; Merck & Co; National Cancer Institute (USA); National Institutes of Health (USA); SCRI Development Innovations
  • Class Antineoplastics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Gastric cancer; Germ cell cancer; Head and neck cancer; Liver cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 03 Feb 2021 Istituto Clinico Humanitas completes a phase I/Ib trial in Mesothelioma and Non-small cell lung cancer (Combination therapy, Late stage disease, First line therapy, Metastatic disease) in Italy (NCT02049060)
  • 22 Jun 2020 Pharmacodynamics data from preclinical studies in Non-small cell lung cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)
  • 16 Jan 2020 ArQule has been acquired and merged into Merck & Co

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top